This Review focuses on micro-ultrasound as a new imaging technology in prostate cancer detection, comparing micro-ultrasound performance with that of the current standard MRI. The potential of micro-ultrasound in other applications, including tumour staging and active surveillance, as well as the use of artificial intelligence to support biopsy decision-making, are also discussed, based on completed and ongoing trials.
John D. Crispino & team suggest that suppression of the substrate receptor FBXO11 causes inefficient ubiquitylation of NPM1, contributing to MDS pathogenesis:
The image shows stronger correlation of NPM1 (magenta) and FBXO11 (green) in the nucleoplasm of CD34+ cells compared with the nucleolar subcompartment.
10 Cyrus Tang Medical Institute, Suzhou Medical Collage, Soochow University, Suzhou, Jiangsu Province, China.
11 Department of Pathology, Northwestern University, Chicago, Illinois, USA.
12 Department of Pathology, Division of Comparative Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA.
By Rachel Tompa
Research led by Stanford Medicine points to the first non-invasive imaging method to visualize senescent cells, which are alive but dormant and play a key role in many diseases.
Quantum computing represents a potential breakthrough technology that could far surpass the technical limitations of modern-day computing systems for some tasks. However, putting together practical, large-scale quantum computers remains challenging, particularly because of the complex and delicate techniques involved.
An example configuration of the proposed laser delivery photonic circuit chip. (Image: Reproduced from DOI:10.1063/5.0300216, CC BY)
Scientists from the CSIR-Central Salt and Marine Chemicals Research Institute (CSMCRI), Indian Institute of Technology Gandhinagar, the Nanyang Technological University, Singapore, and the S N Bose National Centre for Basic Sciences have collaborated to develop a new class of highly precise filtration membranes.
Ultra-precise “POMbranes” sieve out larger molecules (red) while allowing only 1-nanometer-sized species (green) to pass through its pores, enabling sharp molecular sorting. (Image: Central Salt and Marine Chemical Research Institute)
“Artificial intelligence is a so-called general-purpose technology that will fundamentally change our economic and social system,” said Andreas Raff.
How can fears about AI replacing jobs impact trust in democracy? This is what a recent study published in the Proceedings of the National Academy of Sciences hopes to address as a team of researchers from Germany and Austria investigated how the perception of AI replacing jobs could erode trust in political attitudes. This study has the potential to help scientists, legislators, and the public better understand the impact of AI beyond professional and personal markets, and how it could impact political societies.
For the study, the researchers conducted two separate surveys designed to obtain public perception regarding AI’s impact on the job market and how this could influence political attitudes. The first survey was comprised of 37,079 respondents with an average age of 48 years with 48 percent men and 52 percent women from 38 European countries and conducted from April to May 2021. The goal of this first survey was to ascertain perceptions of whether AI was considered as job-replacing or job-creating and how this impacts trust in political establishments. The second survey was comprised of 1,202 respondents from the United Kingdom with an average age of 47 years, and the goal of this second survey was to ascertain perceptions regarding identify causes for this relationship.
In the end, the researchers found that respondents who viewed AI more as job-replacing than job-creating also carried a perception of a lack of trust in political establishments. The researchers also found that respondents who were informed that AI will replace jobs caused them to have a distrust in political establishments.
Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease, affecting up to one in three people in the general population, with an estimated increase in prevalence of more than 50% in the last three decades. The rise in prevalence of MASLD will result in substantial increases in the number patients with decompensated cirrhosis and those developing liver cancer by 2030. Despite the complex pathobiology of MASLD, two major breakthroughs in phase 3 clinical trials now herald an era of licensed therapies for MASLD.